Is CAR T-Cell Therapy the future of Cancer Treatment?

With the growing cancer cases worldwide, governments of different countries are increasingly investing in the healthcare sector & conducting numerous research & development activities to bring out more effective & reliable diagnostics & therapeutics for patients.

Among all, Chimeric Antigen Receptor (CAR) T-cell Therapy is swiftly gaining momentum globally. It is a type of immunotherapy where altered immune cells (T-cells) are used to find & attack tumor cells. In the therapy, a patient's T cells are extracted & genetically engineered to express a CAR (Chimeric Antigen Receptor) to recognize a protein on the surface of cancer cells. The modified T-cells are then multiplied & infused back into the patient. From here, these cells identify & kill tumor cells & might remain in the body for months after the infusion.

With the mounting consumer awareness about the high possibilities of this immunotherapy to show effectiveness in cancer patients, a recent study by MarkNtel Advisors has revealed that the Global Chimeric Antigen Receptor (CAR) T-cell Therapy Market is set to register an exponential CAGR during 2022-27. Now let us read the blog further to learn more about CAR T-cells and what the future holds for this therapy in treating cancer patients.

What are CAR T-Cells & their role in treating cancer?

While surgery, chemotherapy, and radiation therapy have been a foundation & primary therapy for the treatment of cancers for over decades now, immunotherapy exhibiting CAR T-Cells virus therapy is paving the way for new potentials in the treatment of cancers in patients. As conventional therapies continue to remain critical mainstays for cancer treatment, new treatments are playing a prominent role in transforming the outlook for cancer treatment for patients.

In recent years, immunotherapy enlist & strengthen the overall immune system of the patient to attack the tumor and has become another pillar for cancer treatment today. These therapies are becoming immune-boosting drugs with the ability to minimize & eradicate tumors, especially in patients with advanced cancer.

Although the therapy might also result in severe side effects in some patients alongside their slightly longer stays at hospitals for monitoring purposes, its efficacy in the treatment of hematologic malignancies has been well-proved. As a result, more and more patients are opting for this immunotherapy, i.e., promoting the overall industry expansion, where several research activities are ongoing to identify if it could help treat solid tumors.

What does the future hold for CAR T-Cell Therapy?

While the prevalence of cancer is yet to be addressed in mass by addressing challenges associated with the availability, reliability, and affordability of therapeutics, including immunotherapies, CAR T-cells virus therapy is anticipated to bring an opportunistic future for the industry. This prospect is backed by the massive support & encouragement of governments of different countries & health associations making substantial investments & conducting numerous research & development activities to bring more effective treatments. Hence, considering the aspects cited above, we can conclude that the Chimeric Antigen Receptor (CAR) T-cell Therapy industry exhibits remunerative growth opportunities for the leading players in the industry and shall lead the overall market toward substantial growth in the future.